



The role of the gut microbiome in the healthy adult status



Valeria D'Argenio^{a,b,1}, Francesco Salvatore^{a,b,c,*}

^a CEINGE-Biotecnologie Avanzate, via G. Salvatore 486, 80145 Naples, Italy

^b Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, via Pansini 5, 80131 Naples, Italy

^c IRCCS-Fondazione SDN, 80143 Naples, Italy

ARTICLE INFO

Article history:

Received 8 September 2014

Accepted 6 January 2015

Available online 10 January 2015

Keywords:

Human microbiome

Metagenomics

Microbiome dysbiosis

Next-generation sequencing

ABSTRACT

The gut microbiome, which hosts up to 1000 bacterial species that encode about 5 million genes, perform many of the functions required for host physiology and survival. Consequently, it is also known as “our forgotten organ”. The recent development of next-generation sequencing technologies has greatly improved metagenomic research. In particular, it has increased our knowledge about the microbiome and its mutually beneficial relationships with the human host. Microbial colonization begins immediately at birth. Although influenced by a variety of stimuli, namely, diet, physical activity, travel, illness, hormonal cycles and therapies, the microbiome is practically stable in healthy adults. This suggests that the microbiome plays a role in the maintenance of a healthy state in adulthood. Quantitative and qualitative alterations in the composition of the gut microbiome could lead to pathological dysbiosis, and have been related to an increasing number of intestinal and extra-intestinal diseases. With the increase in knowledge about gut microbiome functions, it is becoming increasingly more possible to develop novel diagnostic, prognostic and, most important, therapeutic strategies based on microbiome manipulation.

© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. The human microbiome: general facts and its interaction with the human host

A microbiota is defined as the community of microorganisms, including bacteria, archaea, viruses, and some unicellular eukaryotes, living in a specific environment. A microbiome, on the other hand, is the entire collection of all the genomic elements of a specific microbiota, whereas metagenomics is the field of molecular research that studies the complexity of microbiomes.

In this optics, and considering the human body as an environment, the human microbiota is the entire collection of microorganisms living on the surface and inside our body (Table 1) [1–4]. These communities are important for human physiology, immune system development, digestion and detoxification reactions. In fact, some of these microorganisms residing in the gut encode proteins involved in functions important for the host's health, such as enzymes required for the hydrolysis of otherwise indigestible dietary compounds, and the synthesis of vitamins [5,6]. Consequently, we have two genomes, one inherited from our parents and the other acquired, i.e., the microbiome. This

concept is the basis of the definition of humans as “superorganisms” [7]. The most important difference between these two genomes is that, while the inherited genome remains almost stable during lifetime, the microbiome is extremely dynamic and can be influenced by a number of factors, among which, age [8], diet [9,10], hormonal cycles [11], travel [12], therapies [13], and illness [13].

Humans are born sterile and microbial colonization begins immediately at birth. The establishment of the infant microbiota appears to be mainly influenced by the type of delivery and the subsequent feeding practices [14–17]. In addition, a number of studies have identified a high intra-individual variability in the infant microbiota composition, especially during the first year of life; it assumes a more adult-like pattern when the host reaches 3 years of age [13–16]. A longitudinal microbiome analysis, carried out on different biological samples collected from the same healthy adults at different time points, has shown not only the presence of specific microbial signatures in the body sites evaluated, but also a great intra-individual variability over time [18]. Aging is associated with a number of physiological and biological modifications, and indeed, it has been recently reported that the microbiome composition differs between adults and the elderly [19].

Most of the human adult microbiota lives in the gut. Only in the human colon does microbial cell density exceed 10^{11} cells/g contents, being equivalent to 1–2 kg of body weight [20]. In addition, it has been estimated that the human gut microbiome accounts for more than 5 million different genes [21]. It is now known that over 1,000 different species colonize the human gut [22], all of which belong to a

Abbreviations: IBD, inflammatory bowel disease; NGS, next-generation sequencing; rRNA, ribosomal RNA.

* Corresponding author at: CEINGE-Biotecnologie Avanzate, and Dipartimento di Medicina Molecolare e Biotecnologie Mediche – Ed. 19, Via Sergio Pansini 5, 80131 Naples, Italy.

E-mail address: salvator@unina.it (F. Salvatore).

¹ Both authors contributed equally to this work.

Table 1

Human microbiota composition across the five most extensively studied body sites. Interestingly, the oral and gut microbiota have the highest microbial diversity, while the urogenital tract has the smallest bacterial diversity [See references 1–4].

Human microbial habitats	Human microbiota (10 times more microbial than human cells: 10^{14} vs 10^{13})	
	Most represented Phyla and their relative abundance (%)	Number of species
Oral cavity	<i>Firmicutes</i> (36.7), <i>Bacteroidetes</i> (17.3), <i>Proteobacteria</i> (17.1), <i>Actinobacteria</i> (11.9), <i>Fusobacteria</i> (5.2)	>500
Skin	<i>Actinobacteria</i> (52), <i>Firmicutes</i> (24.4), <i>Proteobacteria</i> (16.5), <i>Bacteroidetes</i> (6.3)	~300
Airways	<i>Actinobacteria</i> (55), <i>Firmicutes</i> (15), <i>Proteobacteria</i> (8), <i>Bacteroidetes</i> (3)	>500
Gut	<i>Firmicutes</i> (38.8), <i>Bacteroidetes</i> (27.8), <i>Actinobacteria</i> (8.2), <i>Proteobacteria</i> (2.1)	>1000
Urogenital tract ^a	<i>Firmicutes</i> (83), <i>Bacteroidetes</i> (3), <i>Actinobacteria</i> (3)	~150

^a Mainly female.

small number of phyla. The most abundant are *Firmicutes*, *Bacteroidetes* and *Actinobacteria*, while *Proteobacteria*, *Fusobacteria*, *Cyanobacteria* and *Verrucomicrobia* are usually less well represented [6]. Remarkably, given this high inter-individual variability in the gut microbiota composition, a core gut microbiome, shared by healthy adults, has been identified, which suggests that it plays a role in the maintenance of health status (Table 2) [23]. To date, a number of functions have been associated to the core microbiome, including polysaccharide digestion, immune system development, defense against infections, synthesis of vitamins, fat storage, angiogenesis regulation, and behavior development [5,6,24,25]. Interestingly, genes encoded by the human core microbiome encode proteins required for host survival, but not present in the human genome, this finding led to the definition of the microbiome as “our forgotten organ” [26].

In this scenario, alterations of the human gut microbiome can play a role in disease development. It is feasible that as we learn more about microbiome composition and functions in healthy individuals, and their modifications associated with specific disease, it will become possible to use the microbiome as a novel target for diagnostic and

Table 2

Human gut microbiota composition throughout life. In healthy conditions, microbial diversity and richness increase with age reach their highest complexity during adulthood. Despite inter- and intra-individual variations, the gut microbiome is practically stable in healthy adults. In the elderly, as in infants, the gut microbiome is more unstable and also has a lower diversity with respect to adults [49].

	Phylum level microbial composition (from the most to the less represented)	Modifying factors
Infant (up to 2–3 years)	<i>Actinobacteria</i> , <i>Proteobacteria</i> , <i>Firmicutes</i> , <i>Bacteroidetes</i>	<ul style="list-style-type: none"> – Vaginal vs caesarian delivery – Gestational age – Infant hospitalization – Breast vs formula fed – Age at solid food introduction – Malnutrition – Antibiotic treatments
Adult	<i>Firmicutes</i> , <i>Bacteroidetes</i> , <i>Actinobacteria</i> , <i>Proteobacteria</i>	<ul style="list-style-type: none"> – Diet – Hormonal cycles – Travel – Therapies – Illness
Elderly (>70 years)	<i>Firmicutes</i> , <i>Actinobacteria</i> , <i>Bacteroidetes</i> , <i>Proteobacteria</i>	<ul style="list-style-type: none"> – Lifestyle changes – Nutritional changes – Increased susceptibility to infections and inflammatory diseases – Use of more medications

therapeutic applications. Here, we review the main techniques now available for metagenomic studies, and the association between microbial dysbiosis and the development of specific diseases.

2. Next-generation sequencing-based approaches for the study of the human microbiome

2.1. Background

The first microbial studies were based on the direct cultivation and isolation of microbes. Although these methodologies are currently used also for diagnostic purposes, they are somewhat limited because the growth conditions used may favor the selection of one or more species over the others. In addition, it is estimated that up to 99% of microbes are currently uncultivable [27]. Other methods, such as quantitative PCR and polyacrylamide gel electrophoresis separation, are also influenced by the use of specific probes for the detection of specific bacteria. Therefore, they are not suitable for the study of entire microbiomes.

Over the past ten years, the rapid development of next-generation sequencing (NGS) technologies, which increase the throughput of bases sequenced/run while reducing sequencing costs, has had a major impact on the field of metagenomics. In fact, a specific microbiome can be qualitatively and quantitatively characterized in-depth using NGS-based approaches without the selection bias and constraints associated with cultivation methods. These technologies are being used also in the Human Microbiome Project, the aim of which is to obtain a complete catalogue of the microbes living in the various districts of the human body and to define their functions [6,21,22].

Although NGS-based strategies have greatly improved our knowledge in the field of metagenomics, they have some limitations. In fact, some technical issues still need to be resolved, and NGS-based strategies depend largely on continuously updated databases, bioinformatic tools, and functional information. The combination of several analytic strategies, including traditional cultivation methods, to characterize the genomic and metabolic properties of specific bacteria will provide further insight into the role of the microbiota, and will also help to identify novel candidate targets for disease diagnosis and treatment.

Below we briefly review the NGS-based strategies that can be used for metagenomic purposes (Fig. 1).

2.2. Shotgun sequencing

Shotgun sequencing is the analysis of an entire microbial community. It is based on the extraction of genomic DNA directly from an environmental sample; this DNA is used to prepare an NGS library for downstream high-throughput sequencing. Subsequent data analysis, performed with specific bioinformatic tools, is required to assign the obtained reads to both the host and its microbial components, and to perform genome assembly. The great advantage of this method is that it avoids both the cultivation and PCR steps since the DNA is directly analyzed. It can also identify bacteria up to species level (the complete, or almost complete, genome can be assembled), and is also used for virome analysis (there is no universal tag for virus analysis). However, the correct assignment of sequencing reads is often difficult due to limitations in the databases currently available as reference. Moreover, genome assembly could be flawed especially in the case of less abundant and/or closely related species. Function assignment may be difficult, and could also be ambiguous. Finally, some biases could be related to the method used for DNA extraction [28].

2.3. 16S rRNA sequencing

Targeted sequencing of specific genes enables one to study the microbiome in all its complexity in an easy and cost-effective manner. All bacteria host the 16S rRNA gene, which is generally used for




Fig. 1. Next Generation sequencing-based approaches for metagenomics. Starting from an environmental sample of interest (1), total DNA and/or RNA are extracted (2). Three different sample preparation strategies can be used depending on the project aims: 16 s rRNA Sequencing, Shotgun Sequencing, and Metatranscriptomics (3). Usually, the 16S rRNA procedure allows sample multiplexing while a higher coverage is required for the others. After sequencing (4), specific bioinformatic pipelines are used for data analysis (5).

phylogenetic purposes. The 16S rRNA gene has a peculiar structure characterized by hypervariable regions spaced by ultra-conserved regions [29]. Therefore, universal primers (by annealing on the conserved regions) can be used to amplify, in a single PCR reaction, virtually all the bacteria present in a target environment, and to unequivocally identify them at the end of sequencing [30]. Although 16S rRNA sequencing has the advantage of being easy to perform, fast and relatively inexpensive, DNA extraction may be biased and the PCR methodology may confound the analysis and produce ambiguous results [28,31]. Also in this case, the assignment of reads depends on the accuracy of the reference databases used, and the procedure does not produce data about bacterial functions.

2.4. Metatranscriptomics

Metatranscriptomics serves to analyze the entire transcriptome of an environmental site to obtain a comprehensive view of gene expression profiles and functional data. Several factors affect the large-scale application of metatranscriptomics, namely, technical issues related to RNA extraction and storage procedures, RNA quality and quantity and, most important, the enrichment procedure used to remove rRNAs. In addition, host contaminations may affect the procedure, and cannot be removed by the currently available rRNA purification methods [32]. Finally, bioinformatic tools for metatranscriptomic data analysis are still being developed.

2.5. Bioinformatic tools

The widespread use of the above-mentioned metagenomic strategies has increased the need for specific data analysis pipelines able to interpret the complex NGS data generated, as reviewed elsewhere [33,34].

Various tools for the analysis of 16S NGS reads have been developed in recent years, and we previously evaluated the performances of two of them in the same dataset [35]. Most of these methods include both taxonomic identification and diversity analysis [36–38]. Taxonomic identification accuracy is variable and depends not only on the specific pipeline used, but also on the portion of the 16S rRNA sequenced, PCR biases and the availability of updated databases. In general, taxonomic assignment is from phylum to genus, while species identification is more difficult [39]. In fact, the 16S rRNA sequencing approach gives a picture of the entire qualitative and quantitative composition of a microbiome, but does not provide information about a specific bacteria genome and/or functions. *In silico* tools for the functional prediction of the most well studied microbiomes, such as the human gut microbiome have recently become available [40].

Shotgun DNA sequencing, which is the NGS sequencing of the whole DNA isolated from an environmental sample, generates the sequence of the host and of all the microbes present in the studied environment, including bacteria, archaea, fungi and viruses, without culture-related and PCR-related biases. Specific tools are available to obtain taxonomic identification up to species and strain levels [41–43]. Besides providing a more accurate identification, with these tools it is possible to make predictions about functional properties. Various pipelines are available for this procedure although they still have computational limitations [44–49]. Metatranscriptomics promises to largely overcome the lack of knowledge and also the ambiguity related to assignment. Indeed, a few tools are already available for this kind of analysis although most depend on the availability of genome reference sequences [50–52].

3. The human microbiome, healthy status and diseases

Various reviews have extensively covered the link between the human microbiome and state of health [see e.g., 53,54]. In this section we will only briefly mention some of the most relevant data related to




Fig. 2. Ileum-associated microbiome composition in a Crohn's disease patient before (patient-BT) and after (patient-AT) nutritional therapy and in a control subject, as characterized by 16S rRNA next-generation sequencing. (a) Note the reduction of Bacteroidetes and the significantly higher prevalence of Proteobacteria in the patient-BT vs the patient-AT and vs the control patient. (b) The heatmap table shows in brownish red the most significant alterations; the numerical figures indicate the number of bacterial families sequenced in each patient. (c) The mean Shannon Diversity Index Score shows significantly lower values in the patient-BT compared with values obtained in the patient-AT and in the control subject ($*P < 0.05$) [69].

this issue. In fact, as the gut core microbiome seems to be almost stable during healthy adulthood, its qualitative and quantitative alterations, which lead of course to functional modifications, has been reported in a number of human diseases [55–58]. In particular, microbial richness, intended as bacterial diversity, is usually considered an indicator of a healthy status: reduced bacterial diversity has been related to obesity and immune-related and inflammatory diseases [55–64]. In addition, as a healthy microbiome composition is required for a number of physiological functions [5,6,24,25], qualitative alterations, especially at level of the core microbiome, can lead to the development of disease. This phenomenon has been mostly studied in inflammatory bowel diseases (IBD), including both Crohn's disease and ulcerative colitis [65–69].

Inflammatory bowel diseases are chronic recurrent disease of the gastrointestinal tract, and are caused by a combination of genetic and environmental factors, including the gut microbiota. A number of studies have reported significant alterations of gut microbial composition in IBD patients compared with not affected individuals [65–69]. Not only do IBD patients have an altered rate of *Bacteroidetes*, *Proteobacteria* and *Firmicutes* colonization, but the bacterial diversity of their microbiome is generally lower than that of controls. In this context, we characterized the 16S rRNA ileum-associated microbiome of a Crohn-affected patient at diagnosis and after nutritional therapy that reduces gut inflammation, and found that the microbial balance was restored by nutritional therapy; in fact, at follow-up the microbial balance did not differ between the patient and control (Fig. 2) [69].

Differences in the gut microbiome between obese and not obese subjects have been also reported and extensively reviewed [62–64]. Although it is well recognized that alterations of gut microbiota and gut permeability can induce the inflammatory status typical of obesity, the specific microbial changes and the mechanisms by which they act, are still unclear. The same applies to an increasing number of intestinal and extra-intestinal diseases [55–58]. The more we learn about the gut microbiota and its functions, the better we will understand the mechanisms underlying a number of diseases, and how to use the microbiota itself as diagnostic and/or prognostic biomarker. Similarly, greater insight into the gut microbiota will enable us to develop novel therapeutic strategies also in the context of an ever more personalized medicine [70].

4. Conclusions and perspectives

Metagenomics has shed considerable light on microbiomes, including the human microbiome, and on the complex relationships between microbes and their hosts. Today, we know that the gut microbiome plays a role in functions required for the physiology and correct development of our organs, and that its composition is related to aging, environmental factors (diet, physical activity, etc.), and pathological conditions. Understanding the role of specific microbes will open the way to novel strategies for disease diagnosis, monitoring and therapy. The modulation of the gut microbiota to gain a healthy status is the challenge facing metagenomic research in coming years.

Acknowledgments

The authors thank Jean Ann Gilder (Scientific Communication srl., Naples, Italy) for editing the text, and Vittorio Lucignano, CEINGE–Biotechnology Avanzate for technical assistance. This work was supported by grant L.5/95 (to F.S.) from the Regione Campania; grant PS 35-126/Ind and grant PON01_02589 (MICROMAP) 2012 from the Ministry of University and Research (both to F.S.); grant RF-2010-2318372 from the Ministry of Health (to F.S.).

References

- [1] Dewhurst FE, Chen T, Izard J, et al. The human oral microbiome. *J Bacteriol* 2010;192:5002–17.
- [2] Grice EA, Kong HH, Conlan S, et al. Topographical and temporal diversity of the human skin microbiome. *Science* 2006;324:1190–2.
- [3] González A, Vázquez-Baeza Y, Knight R. SnapShot: the human microbiome. *Cell* 2014;158:690–690.e1.
- [4] Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. *Nature* 2011;473:174–80.
- [5] Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex carbohydrates in the gut. *Gut Microbes* 2012;3:289–306.
- [6] Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010;464:59–65.
- [7] Walsh CJ, Guinane CM, O'Toole PW, Cotter PD. Beneficial modulation of the gut microbiota. *FEBS Lett* 2014. <http://dx.doi.org/10.1016/j.febslet.2014.03.035>.
- [8] Gajer P, Brotman RM, Bai G, et al. Temporal dynamics of the human vaginal microbiota. *Sci Transl Med* 2012;4:132ra152.
- [9] David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 2014;505:559–63.
- [10] Wu GD, Chen J, Hoffmann C, et al. Linking longterm dietary patterns with gut microbial enterotypes. *Science* 2011;334:105–8.
- [11] Koren O, Goodrich JK, Cullender TC, et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. *Cell* 2012;150:470–80.
- [12] Yatsunen T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. *Nature* 2012;486:222–7.
- [13] Perez-Cobas AE, Gosalbes MJ, Friedrichs A, et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. *Gut* 2013;62:1591–601.
- [14] Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. *PLoS Biol* 2007;5:e177.
- [15] Koenig JE, Spor A, Scalfone N, et al. Succession of microbial consortia in the developing infant gut microbiome. *Proc Natl Acad Sci U S A* 2011;108:4578–85.
- [16] Sharon I, Morowitz MJ, Thomas BC, Costello EK, Relman DA, Banfield JF. Time series community genomics analysis reveals rapid shifts in bacterial species, strains, and phage during infant gut colonization. *Genome Res* 2013;23:111–20.
- [17] Stewart CJ, Marris EC, Nelson A, et al. Development of the preterm gut microbiome in twins at risk of necrotizing enterocolitis and sepsis. *PLoS One* 2013;8:e73465.
- [18] Caporaso JG, Lauber CL, Costello EK, et al. Moving pictures of the human microbiome. *Genome Biol* 2011;12:R50.
- [19] Claesson MJ, Cusack S, O'Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc Natl Acad Sci U S A* 2011;108:4586–91.
- [20] Walker AW, Duncan SH, Louis P, Flint HJ. Phylogeny, culturing, and metagenomics of the human gut microbiota. *Trends Microbiol* 2014;22:267–74.
- [21] Human Microbiome Project Consortium. A framework for human microbiome research. *Nature* 2012;486:215–21.
- [22] Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature* 2012;486:207–14.
- [23] Turnbaugh PJ, Gordon JL. The core gut microbiome, energy balance and obesity. *J Physiol* 2009;587:4153–8.
- [24] Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. *Physiol Rev* 2010;90:859–904.
- [25] Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. *Neurogastroenterol Motil* 2011;23:187–92.
- [26] O'Hara AM, Shanahan F. The gut flora as a forgotten organ. *EMBO Rep* 2006;7:688–93.
- [27] Li L, Mendis N, Trigui H, Oliver JD, Faucher SP. The importance of the viable but non-culturable state in human bacterial pathogens. *Front Microbiol* 2014;5:258.
- [28] Morgan JL, Darling AE, Eisen JA. Metagenomic sequencing of an in vitro-simulated microbial community. *PLoS One* 2010;5:e10209.
- [29] Woese CR, Fox GE, Zablén L, et al. Conservation of primary structure in 16S ribosomal RNA. *Nature* 1975;254:83–6.
- [30] Jumpstart Consortium Human Microbiome Project Data Generation Working Group. Evaluation of 16S rDNA based community profiling for human microbiome research. *PLoS One* 2012;7:e39315.
- [31] Lee CK, Herbold CW, Polson SW, et al. Groundtruthing next-gen sequencing for microbial ecology-biases and errors in community structure estimates from PCR amplicon pyrosequencing. *PLoS One* 2012;7:e44224.
- [32] Giannoukos G, Ciulla DM, Huang K, et al. Efficient and robust RNA-seq process for cultured bacteria and complex community transcriptomes. *Genome Biol* 2012;13:R23.
- [33] Morgan XC, Huttenhower C. Meta'omic analytic techniques for studying the intestinal microbiome. *Gastroenterology* 2014;146:1437–48.
- [34] Logares R, Haverkamp TH, Kumar S, et al. Environmental microbiology through the lens of high-throughput DNA sequencing: synopsis of current platforms and bioinformatics approaches. *J Microbiol Methods* 2012;91:106–13.
- [35] D'Argenio V, Casaburi G, Precone V, Salvatore F. Comparative metagenomic analysis of human gut microbiome composition using two different bioinformatic pipelines. *Biomed Res Int* 2014;2014:325340.
- [36] Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* 2010;7:335–6.
- [37] Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community supported software for describing and comparing microbial communities. *Appl Environ Microbiol* 2009;75:7537–41.
- [38] Meyer F, Paarmann D, D'Souza M, et al. The metagenomics RAST server – a public resource for the automatic phylogenetic and functional analysis of metagenomes. *BMC Bioinformatics* 2008;9:386.
- [39] Vetrovsky T, Baldrian P. The variability of the 16S rRNA gene in bacterial genomes and its consequences for bacterial community analyses. *PLoS One* 2013;8:e57923.
- [40] Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nat Biotechnol* 2013;31:814–21.

- [41] Brady A, Salzberg SL. Phymm and PhymmBL: metagenomic phylogenetic classification with interpolated Markov models. *Nat Methods* 2009;6:673–6.
- [42] Boisvert S, Raymond F, Godzaridis E, Laviolette F, Corbeil J, Ray Meta: scalable de novo metagenome assembly and profiling. *Genome Biol* 2012;13:R122.
- [43] Segata N, Bornigen D, Morgan XC, Huttenhower C. PhyloPhlAn is a new method for improved phylogenetic and taxonomic placement of microbes. *Nat Commun* 2013;4:2304.
- [44] Howe AC, Jansson JK, Malfatti SA, Tringe SG, Tiedje JM, Brown CT. Tackling soil diversity with the assembly of large, complex metagenomes. *Proc Natl Acad Sci U S A* 2014;111:4904–9.
- [45] Namiki T, Hachiya T, Tanaka H, Sakakibara Y. MetaVelvet: an extension of Velvet assembler to de novo metagenome assembly from short sequence reads. *Nucleic Acids Res* 2012;40:e155.
- [46] Peng Y, Leung HC, Yiu SM, Chin FY. Meta-IDBA: a de novo assembler for metagenomic data. *Bioinformatics* 2011;27:i94–i101.
- [47] Delcher AL, Bratke KA, Powers EC, Salzberg SL. Identifying bacterial genes and endosymbiont DNA with Glimmer. *Bioinformatics* 2007;23:673–9.
- [48] Besemer J, Lomsadze A, Borodovsky M. GeneMarkS: a self-training method for prediction of gene starts in microbial genomes. Implications for finding sequence motifs in regulatory regions. *Nucleic Acids Res* 2001;29:2607–18.
- [49] Abubucker S, Segata N, Goll J, et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. *PLoS Comput Biol* 2012;8:e1002358.
- [50] Leimena MM, Ramiro-Garcia J, Davids M, et al. A comprehensive metatranscriptome analysis pipeline and its validation using human small intestine microbiota datasets. *BMC Genomics* 2013;14:530.
- [51] Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and cufflinks. *Nat Protoc* 2012;7:562–78.
- [52] Mandlik A, Livny J, Robins WP, Ritchie JM, Mekalanos JJ, Waldor MK. RNA-Seq-based monitoring of infection-linked changes in *Vibrio cholerae* gene expression. *Cell Host Microbe* 2011;10:165–74.
- [53] Backhed F, Fraser CM, Ringel Y, et al. Defining a healthy human gut microbiome: Current concepts, future directions, and clinical applications. *Cell Host Microbe* 2012;12:611–22.
- [54] Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. *Gastroenterology* 2014;146:1449–58.
- [55] Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. *Gastroenterology* 2014;146:1489–99.
- [56] Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. *Gastroenterology* 2014;146:1513–24.
- [57] Severance EG, Yolken RH, Eaton WW. Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. *Schizophr Res* 2014. <http://dx.doi.org/10.1016/j.schres.2014.06.027>.
- [58] Olivares M, Neef A, Castillejo G, et al. The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease. *Gut* 2014. <http://dx.doi.org/10.1136/gutjnl-2014-306931>.
- [59] Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. *Nature* 2013;500:541–6.
- [60] Wang Y, Hoenig JD, Malin KJ, et al. 16S rRNA gene based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. *ISME J* 2009;3:944–54.
- [61] Bisgaard H, Li N, Bonnelykke K, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. *J Allergy Clin Immunol* 2011;128:646–52.
- [62] Cani PD. Gut microbiota and obesity: lessons from the microbiome. *Brief Funct Genomics* 2013;12:381–7.
- [63] Clarke SF, Murphy EF, Nilaweera K, et al. The gut microbiota and its relationship to diet and obesity: new insights. *Gut Microbes* 2012;3:186–202.
- [64] Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. *Lancet Diabetes Endocrinol* 2014. [http://dx.doi.org/10.1016/S2213-8587\(14\)70134-2](http://dx.doi.org/10.1016/S2213-8587(14)70134-2).
- [65] Frank DN, Amand ALS, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A* 2007;104:13780–5.
- [66] Sokol H, Seksik P. The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. *Curr Opin Gastroenterol* 2010;26:327–31.
- [67] Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. *BMC Microbiol* 2011;11:7.
- [68] Elson CO, Cong Y. Host-microbiota interactions in inflammatory bowel disease. *Gut Microbes* 2012;3:332–44.
- [69] D'Argenio V, Precone V, Casaburi G, et al. An altered gut microbiome profile in a child affected by Crohn's disease normalized after nutritional therapy. *Am J Gastroenterol* 2013;108:851–2.
- [70] Lemon KP, Armitage GC, Relman DA, Fischbach MA. Microbiotatargeted therapies: an ecological perspective. *Sci Transl Med* 2012;4:137rv5.